ReviewLa Radiologia medica2025
Advances in renal cancer: diagnosis, treatment, and emerging technologies.
Review in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- JJR-TOP GUN Phase 2: broadening the scope through advances in radiology and interdisciplinary innovation.Japanese journal of radiology · 2026Article
- A mast cell-associated apoptosis-related transcriptomic signature in clear cell renal cell carcinoma andFrontiers in immunology · 2026Article
- Study on the prediction of postoperative metastasis in renal cancer using perirenal fat CT radiomics combined with clinical features.Frontiers in oncology · 2026Article
- The Role and Therapeutic Potential of the cGAS-STING Signaling Pathway in Alzheimer's Disease.Brain and behavior · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comprehensive overview of current practices and recent advancements in the diagnosis and treatment of renal cancer. It introduces updates in histological classification and explains the imaging characteristics of each tumour based on these changes. The review highlights state-of-the-art imaging modalities, including magnetic resonance imaging, computed tomography, positron emission tomography, and ultrasound, emphasising their crucial role in tumour characterisation and optimising treatment planning. Emerging technologies, such as radiomics and artificial intelligence, are also discussed for their transformative impact on enhancing diagnostic precision, prognostic prediction, and personalised patient management. Furthermore, the review explores current treatment options, including minimally invasive techniques such as cryoablation, radiofrequency ablation, and stereotactic body radiation therapy, as well as systemic therapies such as immune checkpoint inhibitors and targeted therapies.
Indexed as
Identifiers
40751897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.